Analyzing...
Loading company...
Supriya Lifescience Ltd. supplies active pharmaceuticals ingredients (“APIs”), with a focus on research and development. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2021-12-28. The company focuses on products in various therapeutic segments, such as Antihistamine, Anti-Allergic, Vitamins, Anesthetics, Ant-Malarial and Anti-Asthmatics. The company handles chemical reactions, such as Friedel Craft’s Acylation, Claisen Condensation, Grignard Reaction, Mannich Reaction, Ritter Reaction, Eschweiler Clark reaction, Hydrogenation, Chlorination, Bromination, Decyanation, Isocyanation, Ethoxylation, Nitration, Alkylation, Reduction, Oxidation, Etherification, Chlorosulphonation, Phosphorylation, Chiral resolution, Heterocyclic chemistry, Thermal ring expansion and Protection/Deprotection. Its manufacturing facilities include delineated areas for quality check; manufacturing areas with multiple clean rooms; engineering and maintenance; warehouse; materials and finished goods stores; in-house microbiological laboratory, and functional waste treatment plant.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹828 Cr revenue.
COGS 30.7%, employees 11.7%.
“We would like to reiterate our guidance of achieving around 20% of annual revenue growth with EBITDA margins in the range of 33 to 35%.”
“Our journey towards 1,000 crore revenue by financial year twenty seven is well on track”
“Revenue for the quarter stood at rupees 200 crores, reflecting a growth of 20% year on year at 38% subsequently.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 17.5%▲ | 10.3% |
| ROCE | 22.4%▲ | 13.7% |
| Net Margin | 24.9%▲ | 7.6% |
| EBITDA Margin | 36.4%▲ | 15.4% |
| Debt To Equity | 0.00x▼ | 0.15x |
Revenue segment breakdown not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | ₹828 Cr +18.9% | ₹696 Cr +22.1% | ₹570 Cr +23.7% | ₹461 Cr -13.0% | ₹530 Cr |
| Other Income | ₹11 Cr +17.0% | ₹10 Cr -7.7% | ₹11 Cr +12.1% | ₹9 Cr +25.2% | ₹8 Cr |
| Total Income | ₹839 Cr +18.8% | ₹706 Cr +21.6% | ₹581 Cr +23.5% | ₹470 Cr -12.5% | ₹538 Cr |
| COGS | ₹254 Cr +20.3% | ₹211 Cr -4.8% | ₹222 Cr +22.6% | ₹181 Cr -7.7% | ₹196 Cr |
| ₹564 Cr +23.2% | ₹458 Cr +10.2% | ₹415 Cr +19.7% | ₹347 Cr +5.0% | ₹330 Cr | |
| Profit Before Tax | ₹275 Cr +10.6% | ₹248 Cr +50.0% | ₹166 Cr +34.2% | ₹123 Cr -40.4% | ₹207 Cr |
| Exceptional Items | (₹0.46 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| ₹66 Cr +8.5% | ₹61 Cr +29.9% | ₹47 Cr +38.5% | ₹34 Cr -39.3% | ₹55 Cr | |
| Net Profit | ₹209 Cr +11.3% | ₹188 Cr +57.8% | ₹119 Cr +32.6% | ₹90 Cr -40.8% | ₹152 Cr |
| Other Comprehensive Income | (₹0.10 Cr) +20.8% | (₹0.13 Cr) ↓ Decline | ₹2 Cr ↑ Recovery | (₹1 Cr) -299.0% | (₹0.32 Cr) |
| EPS | ₹25.98 | ₹23.35 | ₹14.80 | ₹11.16 | ₹18.86 |
| Diluted Shares | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Supriya Lifescience Limited has informed the Exchange about Copy of Newspaper Publication
Supriya Lifescience Limited has informed the Exchange regarding Notice of Postal Ballot
Satish Waman Wagh has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations,...
Supriya Lifescience Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Supriya Lifescience Limited has informed the Exchange about Schedule of meet
Supriya Lifescience Limited has informed the Exchange about Transcript
Supriya Lifescience Limited has informed the Exchange about Link of Recording
Supriya Lifescience Limited has informed the Exchange about Copy of Newspaper Publication
Supriya Lifescience Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Press Release - Audited Financial Results for quarter and year ended March 31, 2026".
Supriya Lifescience Limited has informed the Exchange about Schedule of meet
Disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015 - Update on inspection by United States Food & Drug Administration (USFDA)
Supriya Lifescience Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
The Exchange had sought clarification from Supriya Lifescience Limited for the quarter ended 31-Dec-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Reg...
Supriya Lifescience Limited has informed the Exchange regarding Notice of Postal Ballot
The Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 31-Dec-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Reg...